Dr. Mark Barsamian, DO

NPI: 1821204207
Total Payments
$457.23
2024 Payments
$180.97
Companies
5
Transactions
9
Medicare Patients
935
Medicare Billing
$303,968

Payment Breakdown by Category

Food & Beverage$357.24 (78.1%)
Education$99.99 (21.9%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Food and Beverage $357.24 8 78.1%
Education $99.99 1 21.9%

Top Paying Companies

Company Total Records Latest Year
Mallinckrodt Hospital Products Inc. $194.61 4 $0 (2024)
Biogen, Inc. $113.54 2 $0 (2024)
Aerie Pharmaceuticals, Inc. $111.89 1 $0 (2018)
ABBVIE INC. $21.42 1 $0 (2024)
Bausch & Lomb Americas Inc. $15.77 1 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $180.97 5 Biogen, Inc. ($113.54)
2023 $164.37 3 Mallinckrodt Hospital Products Inc. ($164.37)
2018 $111.89 1 Aerie Pharmaceuticals, Inc. ($111.89)

All Payment Transactions

9 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
10/17/2024 Biogen, Inc. BYOOVIZ (Biological) Food and Beverage In-kind items and services $94.90 General
Category: Ophthalmology
07/10/2024 Mallinckrodt Hospital Products Inc. ACTHAR (Biological) Food and Beverage In-kind items and services $30.24 General
Category: IMMUNOLOGY
06/10/2024 Biogen, Inc. BYOOVIZ (Biological) Food and Beverage In-kind items and services $18.64 General
Category: Ophthalmology
05/16/2024 Bausch & Lomb Americas Inc. VYZULTA (Drug) Food and Beverage In-kind items and services $15.77 General
Category: Ophthalmology
05/15/2024 ABBVIE INC. LUMIGAN (Drug) Food and Beverage In-kind items and services $21.42 General
Category: EYE CARE
11/02/2023 Mallinckrodt Hospital Products Inc. ACTHAR (Biological) Food and Beverage In-kind items and services $34.86 General
Category: IMMUNOLOGY
10/06/2023 Mallinckrodt Hospital Products Inc. ACTHAR (Biological) Education In-kind items and services $99.99 General
Category: IMMUNOLOGY
09/14/2023 Mallinckrodt Hospital Products Inc. ACTHAR (Biological) Food and Beverage In-kind items and services $29.52 General
Category: IMMUNOLOGY
10/27/2018 Aerie Pharmaceuticals, Inc. Rhopressa (Drug) Food and Beverage In-kind items and services $111.89 General
Category: Ophthalmology

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 4 124 148 $50,168 $10,532
2022 4 66 127 $25,307 $8,555
2021 5 131 228 $49,558 $15,919
2020 9 614 1,590 $554,518 $268,962
Total Patients
935
Total Services
2,093
Medicare Billing
$303,968
Procedure Codes
22

All Medicare Procedures & Services

22 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99204 New patient office or other outpatient visit, 45-59 minutes Office 2023 47 47 $30,710 $6,335 20.6%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 11 18 $8,092 $1,864 23.0%
92134 Imaging of retina Office 2023 37 52 $8,266 $1,714 20.7%
92201 Extended exam of the back part of the eye with retinal drawing Office 2023 29 31 $3,100 $618.45 20.0%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2022 15 24 $8,184 $3,275 40.0%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 15 21 $5,292 $2,038 38.5%
92134 Imaging of retina Office 2022 25 68 $7,169 $1,922 26.8%
92014 Established patient complete exam of visual system Office 2022 11 14 $4,662 $1,320 28.3%
92014 Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits Office 2021 30 46 $15,318 $4,987 32.6%
92134 Diagnostic imaging of retina Office 2021 54 120 $12,681 $3,839 30.3%
99215 Established patient outpatient visit, total time 40-54 minutes Office 2021 19 21 $7,161 $3,229 45.1%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 17 22 $5,544 $2,022 36.5%
67028 Injection of drug into eye Office 2021 11 19 $8,854 $1,842 20.8%
J0178 Injection, aflibercept, 1 mg Office 2020 35 160 $171,840 $116,689 67.9%
J2778 Injection, ranibizumab, 0.1 mg Office 2020 28 359 $173,253 $97,139 56.1%
67028 Injection of drug into eye Office 2020 90 246 $133,991 $19,248 14.4%
92012 Eye and medical examination for diagnosis and treatment, established patient Office 2020 166 251 $31,375 $14,605 46.6%
92134 Diagnostic imaging of retina Office 2020 203 432 $28,285 $13,263 46.9%
J9035 Injection, bevacizumab, 10 mg Office 2020 34 83 $7,296 $4,448 61.0%
92004 Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits Office 2020 22 22 $4,070 $1,713 42.1%
92014 Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits Office 2020 16 16 $2,224 $1,193 53.6%
92250 Photography of the retina Office 2020 20 21 $2,184 $663.82 30.4%

About Dr. Mark Barsamian, DO

Dr. Mark Barsamian, DO is a Retina Specialist healthcare provider based in Hopedale, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/15/2007. The National Provider Identifier (NPI) number assigned to this provider is 1821204207.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Barsamian, DO has received a total of $457.23 in payments from pharmaceutical and medical device companies, with $180.97 received in 2024. These payments were reported across 9 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($357.24).

As a Medicare-enrolled provider, Barsamian has provided services to 935 Medicare beneficiaries, totaling 2,093 services with total Medicare billing of $303,968. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.

Practice Information

  • Specialty Retina Specialist
  • Other Specialties Retina Specialist
  • Location Hopedale, MA
  • Active Since 05/15/2007
  • Last Updated 01/29/2026
  • Taxonomy Code 207WX0107X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1821204207

Products in Payments

  • ACTHAR (Biological) $194.61
  • BYOOVIZ (Biological) $113.54
  • Rhopressa (Drug) $111.89
  • LUMIGAN (Drug) $21.42
  • VYZULTA (Drug) $15.77

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.